Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
So the question worth asking is not only whether something is FDA-approved
DNA damage-inducing anticancer therapies: from global to precision damage
1334-C A 7th-YEAR INTERIM ANALYSIS OF PROSPECTIVE AND LONGITUDINAL KOREAN CHRONIC HEPATITIS B COHORT Jae Seung Lee 1 , Beom Kyung Kim 1 , Hye Won Lee 1 , Seung Up Kim 1 , Do Young Kim 1 , Sang Hoon Ahn 1 , Sang Gyune Kim 2 , Eun Young Cho 3 , Young Mi Hong 4 , Ki Tae Yoon 4 , Yeon Seok Seo 5 and Jun Yong Park 1 , (1)Yonsei University College of Medicine, Seoul, Republic of Korea, (2)Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Republic of Korea, (3)Wonkwang University College of Medicine, Iksan, Republic of Korea, (4)Pusan National University Hospital, Busan, Republic of Korea, (5)Korea University Anam Hospital, Korea University Medical College, Seoul, Korea, Republic of (South) Background: We aimed to report the clinical outcome of Korean chronic hepatitis B (CHB) patients from a prospective longitudinal cohort
(PubMed) Vidal-Casariego A, Burgos-Pelaez R, Martinez-Faedo C, et al
US$ 29.70
US$ 23.64
US$ 29.32
US$ 27.66
US$ 22.15
